In addition to the keynote presentation by Dr. DiPersio on bone marrow transplantation and the role of CXCR4 in cancer, additional topics for discussion at the ongoing BioLineRx investor breakfast meeting include: (i) presentation on BL-8040 clinical development plans in immuno-oncology combinations and AML, as well as on the upcoming GENESIS Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation in multiple myeloma patients; (ii) presentation of AGI-134, the Company's novel immuno-oncology project; and (iii) an overview of the Company's plans and expected milestones for 2018.
BioLineRx is hosting a live webcast of the investor breakfast today between
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and is expected to initiate a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which is expected to initiate a first-in-man study in the first half of 2018. In addition, BioLineRx has a strategic collaboration with
For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's
Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the
View original content:http://www.prnewswire.com/news-releases/biolinerx-ltd-hosts-investor-breakfast-meeting-in-ny-300566737.html